STOCK TITAN

Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Metagenomi Therapeutics, Inc. director Juergen Eckhardt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company's 2027 annual meeting of stockholders, subject to his continued service with the company. After this award, he holds 21,000 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Eckhardt Juergen
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 21,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 21,000 shares (Direct)
Footnotes (1)
  1. F1. The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Stock options granted 21,000 options Grant to director Juergen Eckhardt
Exercise price $1.23 per share Strike price for granted options
Underlying shares 21,000 shares Common stock underlying the options
Post-grant option holdings 21,000 options Total options held after this transaction
Option expiration date June 8, 2036 Expiration of granted options
Vesting condition Earlier of 1-year from grant or 2027 meeting Subject to continued service
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.2300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Metagenomi Therapeutics (MGX) report for Juergen Eckhardt?

Metagenomi Therapeutics reported that director Juergen Eckhardt received a grant of stock options for 21,000 shares of common stock. These options are part of his compensation and were not an open-market stock purchase or sale.

What is the exercise price of the new MGX stock options granted to Juergen Eckhardt?

The stock options granted to Juergen Eckhardt have an exercise price of $1.23 per share. This means he can buy Metagenomi Therapeutics common stock at $1.23 per share once the options vest and become exercisable.

When do Juergen Eckhardt’s Metagenomi Therapeutics (MGX) options vest?

The options will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual stockholders’ meeting. Vesting is conditioned on his continued service with Metagenomi Therapeutics through that date.

How many Metagenomi Therapeutics (MGX) options does Juergen Eckhardt hold after this grant?

After this grant, Juergen Eckhardt holds 21,000 stock options directly. Each option relates to one share of Metagenomi Therapeutics common stock, reflecting his full derivative position reported in this filing.

When do Juergen Eckhardt’s MGX stock options expire?

The granted stock options are scheduled to expire on June 8, 2036. If the options are not exercised by that expiration date after vesting, the right to buy Metagenomi Therapeutics shares at $1.23 per share will lapse.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Eckhardt Juergen

(Last)(First)(Middle)
C/O METAGENOMI THERAPEUTICS, INC.
5959 HORTON STREET, 7TH FLOOR

(Street)
EMERYVILLE CALIFORNIA 94608

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Metagenomi Therapeutics, Inc. [ MGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.2306/09/2026A21,000 (1)06/08/2036Common Stock21,000$021,000D
Explanation of Responses:
1. The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.
/s/ Matthew L. Wein, attorney-in-fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)